- Teleflex ( NYSE: TFX ) said the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to the Triumph Catheter, and the first clinical use of GuideLiner Coast Catheter, indicated for complex percutaneous coronary interventions
- The Triumph Catheter was designed in collaboration with Bill Nicholson, Director of Interventional Cardiology at Emory Healthcare, Atlanta. The device features a design with six wire exit ports to advance wires precisely and for clear visualization, the company added.
- Teleflex noted that the GuideLiner Coast Catheter adds a hydrophilic option to its guide extension portfolio — led by the flagship GuideLiner V3 Catheter—enabling physicians to select the level of deliverability and backup support required for specific cases.
- Earlier this year, the GuideLiner Coast Catheter was first used in a clinical procedure at the UW Medicine Heart Institute in Seattle, according to the company.
- The GuideLiner Coast Catheter is currently in a limited market release phase, with full release expected later in the year, Teleflex added.
For further details see:
Teleflex's 2 catheter devices get FDA clearance